Trending...
- Maryland: Urban Agriculture Advisory Committee Meeting Notice
- PUBLIC NOTICE UPDATE: Maryland Agencies to Treat Potomac River for Black Fly Control on June 30
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
HALETHORPE, Md., Sept. 24, 2024 ~ Fzata, Inc. has recently been awarded a five-year non-dilutive grant of up to $7 million by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS). The grant, with the identification number UG3NS135350, will also include in-kind contributions and will support the development of Fzata's drug candidate FZ006 as an oral treatment for chronic visceral pain associated with inflammatory bowel syndrome (IBS).
The grant is a collaboration between Fzata and the University of Maryland, Baltimore (UMB), with the aim of advancing the development of FZ006. This drug candidate is being developed as a safe and effective option for treating chronic abdominal pain without the risk of addiction.
Dr. Zhiyong Yang, President and CEO of Fzata, expressed his excitement about this opportunity to address a serious unmet need. He stated that 10-15% of Americans suffer from severe pain associated with IBS, but current treatment options are often inadequate. The most effective treatments involve opioids, which come with a high risk of addiction. FZ006 aims to be the first non-addictive option for treating chronic abdominal pain.
More on Marylandian
The team at Fzata is looking forward to working with their collaborators at UMB and NINDS to bring this game-changing treatment to IBS patients and their families. Dr. Yang believes that this collaboration will lead to significant advancements in their pipeline, including their drug candidate FZ002 for C. difficile infections.
Phil Robilotto, DO, MBA, associate vice president of technology transfer at UMB and director of UM Ventures in Baltimore, also expressed his enthusiasm for this partnership. He stated that it presents a wonderful opportunity for one of UMB's startup portfolio companies to advance their platform technology for an important medical need. He also mentioned that they are excited about Fzata's continued pipeline advancements, including FZ002, which is expected to start first-in-human clinical trials in 2025. This drug candidate is based on technology licensed from UMB.
The grant will support various activities, including IND-enabling studies, GLP toxicology, cGMP manufacturing, phase 1 trial design, IND submission, and a Phase 1a clinical trial. With this support from NINDS and the collaboration between Fzata and UMB, there is hope for a safe and effective treatment for chronic abdominal pain associated with IBS in the near future.
The grant is a collaboration between Fzata and the University of Maryland, Baltimore (UMB), with the aim of advancing the development of FZ006. This drug candidate is being developed as a safe and effective option for treating chronic abdominal pain without the risk of addiction.
Dr. Zhiyong Yang, President and CEO of Fzata, expressed his excitement about this opportunity to address a serious unmet need. He stated that 10-15% of Americans suffer from severe pain associated with IBS, but current treatment options are often inadequate. The most effective treatments involve opioids, which come with a high risk of addiction. FZ006 aims to be the first non-addictive option for treating chronic abdominal pain.
More on Marylandian
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
The team at Fzata is looking forward to working with their collaborators at UMB and NINDS to bring this game-changing treatment to IBS patients and their families. Dr. Yang believes that this collaboration will lead to significant advancements in their pipeline, including their drug candidate FZ002 for C. difficile infections.
Phil Robilotto, DO, MBA, associate vice president of technology transfer at UMB and director of UM Ventures in Baltimore, also expressed his enthusiasm for this partnership. He stated that it presents a wonderful opportunity for one of UMB's startup portfolio companies to advance their platform technology for an important medical need. He also mentioned that they are excited about Fzata's continued pipeline advancements, including FZ002, which is expected to start first-in-human clinical trials in 2025. This drug candidate is based on technology licensed from UMB.
The grant will support various activities, including IND-enabling studies, GLP toxicology, cGMP manufacturing, phase 1 trial design, IND submission, and a Phase 1a clinical trial. With this support from NINDS and the collaboration between Fzata and UMB, there is hope for a safe and effective treatment for chronic abdominal pain associated with IBS in the near future.
Filed Under: Business
0 Comments
Latest on Marylandian
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- RestoraPet of Gaithersburg, MD acquired by Individual Entrepreneur of Rochester, MI
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- YYNOT Brings High-Energy RUSH Tribute to the Weinberg Center this September
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact